Faculty Collaboration Database

Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002 Jul;11(4):326-30; quiz 331-2

Date

07/10/2002

Pubmed ID

12102433

DOI

10.4037/ajcc2002.11.4.326

Scopus ID

2-s2.0-0036635855   24 Citations

Abstract

Although nearly 10% of patients experience profound vasodilatory shock after cardiopulmonary bypass, some patients remain refractory to traditional resuscitation. Among this subset are patients who have inappropriately low levels of endogenous vasopressin. Thus, vasopressin replacement is an intuitively attractive intervention. The purposes of this review are to outline the pathophysiology of vasodilatory shock after cardiopulmonary bypass, to discuss the physiological role of endogenous vasopressin, to explore the clinical basis for vasopressin replacement, and to review the pharmacology and dosing guidelines.

Author List

Albright TN, Zimmerman MA, Selzman CH

Author

Michael A. Zimmerman MD, FACS Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Cardiopulmonary Bypass
Coronary Care Units
Education, Continuing
Humans
Practice Guidelines as Topic
Shock, Surgical
Systemic Inflammatory Response Syndrome
United States
Vasopressins